Relation of Serum Adiponectin Levels to Number of Traditional Atherosclerotic Risk Factors and All-Cause Mortality and Major Adverse Cardiovascular Events (from the Copenhagen City Heart Study)

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Soren Lindberg
  • ,
  • Rasmus Mogelvang
  • ,
  • Sune H Pedersen, Denmark
  • Mette Bjerre
  • Jan Frystyk
  • Allan Flyvbjerg, Denmark
  • Søren Galatius, Institut for Klinisk Medicin, Denmark
  • Jan Skov Jensen, Kirurgi og Intern Medicin, Denmark
Adiponectin exerts anti-inflammatory and antiatherogenic effects and appears to protect against arteriosclerosis. Accordingly, an association between low concentrations of plasma adiponectin and cardiovascular (CV) disease has been demonstrated in several studies. In contrast, elevated plasma adiponectin has been associated with increased mortality and an increasing number of major adverse CV events (MACE). Because of these conflicting results, the true role of adiponectin remains to be elucidated. In the Copenhagen City Heart Study, we prospectively followed up 5,624 randomly selected men and women from the community without CV disease. Plasma adiponectin was measured at the beginning of the study. The median follow-up time was 7.8 years (interquartile range 7.3 to 8.3). The end point was all-cause mortality (n = 801), and the combined end point was MACE, consisting of CV mortality or nonfatal myocardial infarction or ischemic stroke (n = 502). High adiponectin was inversely associated with an increasing number of traditional CV risk factors (p
Original languageEnglish
JournalAmerican Journal of Cardiology
Pages (from-to)1139-45
Number of pages7
Publication statusPublished - 2013

See relations at Aarhus University Citationformats

ID: 52463662